Abstract
9041 Background: αPD-1 therapy yields objective clinical responses in 30-40% of advanced melanoma (MEL) patients (pts). While promising, many pts do not benefit clinically. Predictive biomarkers to...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
